July 19, 2019  |  

Emergence of ebola virus escape variants in infected nonhuman primates treated with the MB-003 antibody cocktail.

Authors: Kugelman, Jeffrey R and Kugelman-Tonos, Johanny and Ladner, Jason T and Pettit, James and Keeton, Carolyn M and Nagle, Elyse R and Garcia, Karla Y and Froude, Jeffrey W and Kuehne, Ana I and Kuhn, Jens H and Bavari, Sina and Zeitlin, Larry and Dye, John M and Olinger, Gene G and Sanchez-Lockhart, Mariano and Palacios, Gustavo F

MB-003, a plant-derived monoclonal antibody cocktail used effectively in treatment of Ebola virus infection in non-human primates, was unable to protect two of six animals when initiated 1 or 2 days post-infection. We characterized a mechanism of viral escape in one of the animals, after observation of two clusters of genomic mutations that resulted in five nonsynonymous mutations in the monoclonal antibody target sites. These mutations were linked to a reduction in antibody binding and later confirmed to be present in a viral isolate that was not neutralized in vitro. Retrospective evaluation of a second independent study allowed the identification of a similar case. Four SNPs in previously identified positions were found in this second fatality, suggesting that genetic drift could be a potential cause for treatment failure. These findings highlight the importance selecting different target domains for each component of the cocktail to minimize the potential for viral escape. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Journal: Cell reports
DOI: 10.1016/j.celrep.2015.08.038
Year: 2015

Read publication

Talk with an expert

If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.